gbola amusa md cfa head hc research
sale trade et
sale trade et
share mil
creat bluematrix
initi buy replic improv
initi coverag replimun buy rate
potenti pipelin boost respons immun
checkpoint inhibitor rang solid tumor indic replimun
develop oncolyt viral ov therapi design
stimul multipl innat adapt immun pathway trigger
robust respons patient tumor posit work
combin increasingly-ubiquit agent
compani pipelin contain asset express gm-csf
express antibodi
express along immune-stimulatori ligand
replimun current evalu intratumor administr
/- bristol-my squibb unrat nivolumab
phase ii portion phase i/ii studi checkpoint-
control phase ii studi /- regeneron unrat
cemiplimab cutan squamou cell carcinoma cscc set begin
near term model mm mm risk-
adjust sale cscc advanc solid tumor
respect togeth account pt replimun
subsequ asset layer addit transgen
promot immun respons tumor type less respons checkpoint
inhibitor express slate enter clinic
less checkpoint-respons tumor express
along immun stimulatori ligand
expect enter clinic
replimun well-character rel derisk viral
platform program expect clinic multipl
data readout next month see multipl reason
posit replimun
essenti better imlyg t-vec unrat
ov approv us melanoma
replimun manag involv develop t-vec
express transgen key improv design
formul us posit better efficaci uptak
prior fda approv t-vec partial derisk safeti
promis earli clinic data combo posit
read-across efficaci melanoma cancer
clinic program rang tumor type provid multipl
opportun success upsid sourc non-
pleas refer import disclosur inform regul analyst certif found page report
posit part combin regimen us increas po base
complementari biolog mechan provid path larger patient popul associ earli
initi registration-direct phase ii studi /- cemiplimab cscc
initi phase studi /- less immun checkpoint inhibitor ici -respons tumor
report initi result phase studi /- nivolumab
initi phase studi tumor
report result phase studi less ici-respons tumor
report result phase ii studi /- nivolumab
report result randomized-control phase ii studi cscc
report result phase ii studi less ici-respons tumor
price target base probability-adjust model key franchis use dcf wacc
perpetu growth impli termin ebitda multipl deriv price target
npv/share cutan squamou cell carcinoma cscc cscc assum
cemiplimab combin regimen penetr us cscc patient cured/treat surgeri
assum launch calendar year averag price per patient treat assum
european sale us sale lag rest world sale european sale
year lag appli risk adjust mm non-risk-adjust sale deriv mm global
npv/share advanc solid tumor melanoma assum ov therapi penetr
stage iii/iv us patient assum combin agent take volum share
metastat bladder cancer assum penetr ov therapi patient
combin take volum share msi-high cancer assum
ov therapi penetr patient advanced/refractori diseas combin anti-
take share volum model initi us price calendar year launch
assum european sale us sale lag rest world sale european sale
lag appli launch probabl bn non-risk-adjust sale deriv mm
intern program npv/share model npv/share solid tumor npv/
share earli discoveri program non-checkpoint-respons cancer type
net cash npv/share replimun cash posit recent stood mm march
risk achiev target price
clinic risk replimun lead asset parallel unrat imlyg fda-approv oncolyt viru
ov viral platform transgen still possibl unanticip advers event may emerg replimun
on-going plan clinic trial product use immulyt platform similarli although preclin
data suggest robust efficaci replimun asset multipl tumor model possibl demonstr
strong efficaci target patient popul either scenario price target could see
regulatori rel genet medicin ever approv use global imlyg thu
far approv hsv-base therapeut limit preced creat regulatori unknown replimun
program even replimun asset achiev target clinic endpoint endpoint trial design deem
suffici approv result delay risk-adjust project price target would therefor expos
commerci potenti may larg expect could due
rel complex intratumor administr compar intraven oral therapi well competit
outsid ov space among ov highlight competit imlyg current sever trial
combin checkpoint inhibitor merck unrat cavatak targovax unrat melanoma
page
checkpoint-respons tumor type outsid ov space numer addit platform develop
promot immun respons cancer includ approach buy nektar therapeut
unrat unrat idera pharma unrat
intellectu properti replimun file patent applic cover immulyt platform understand
applic pend march patent grant protect asset beyond
termin valuat price target may affect
financ risk replimun may need rais addit capit perhap via equiti financ reach
profit potenti result share dilut sharehold
stock price volatil share price volatil common development compani biotechnolog sector
replimun clinical-stag biotechnolog compani focus develop oncolyt viral therapeut
employ immulyt platform first asset pipelin design increas respons
rate combin checkpoint respons tumor type includ cutan squamou cell carcinoma
advanc melanoma non-melanoma skin cancer bladder cancer microsatellite-inst high msi-high
cancer compani also develop target less checkpoint respons tumor indic replimun
incorpor headquart woburn massachusett
page
summari replimun develop next-gen ov therapi enhanc ici respons
risk replimun thesi
chardan cscc model model mm risk-adjust sale npv/share
chardan ici-respons tumor model model mm risk-adjust sale npv/sh
catalyst replimun anticip multipl data readout next month
pipelin replimun immulyt platform target rang solid tumor /- ici
immulyt platform next-gen ov enhanc lytic immun stimul activ
unmet need oncolog minor patient respond checkpoint inhibitor even approv indic
replimun pipelin design address cancer indic differ level ici respons
oncolyt virus design strengthen immun respons tumor via multipl mechan
talimogen laherparepvec t-vec imlyg fda-approv oncolyt viru limit
ici t-vec work better togeth melanoma expect ov/ici synergi extend cancer
replimun immulyt platform incorpor fusogen protein galv-gp increas ov potenc immunogen
replimun platform offer key advantag t-vec
lead candid trigger tumor regress increas cell immunocompet preclin model
also show synergi preclin model
clinic strategi increas efficaci checkpoint-respons solid tumor indic
trial evalu safeti efficaci monotherapi combin
phase studi assess direct inject image-guid inject deeper tumor parallel cohort
replimun enrol patient phase ii portion studi
replimun fast-to-market strategi /- regeneron therapi cemiplimab aim increas cr rate
one number oncolyt viru therapi develop melanoma hot tumor
deliv potent immun activ factor tumor
mous surrog show efficaci lower dose vs cooper induc immun memori
preclin data show addit individu immun stimulatori ligand also increas potenc
among suit next-gen oncolyt virus develop cold tumor
sale key product
page
summari replimun develop next-gen ov therapi enhanc ici respons
initi coverag replimun buy rate base potenti hsv-base oncolyt viru
platform increas rate durat respons immunotherapi rang solid tumor type becom
increasingli appreci i/o field optim anti-tumor respons requir engag multipl immun
pathway control initi recognit tumor antigen cell stimul innat immun cell infiltr
immun cell tumor circumvent immunosuppress signal checkpoint metabol factor
cytokin other ici address part addit agent clea
rli need increas proport respond patient expand type tumor respond
immunotherapi number approach develop target paramet among
oncolyt virus ov repres multi-prong strategi target cancer via complementari mechan involv
pathway figur replimun immulyt platform base herp simplex type viru
viru use unrat imlyg talimogen laherparepvec t-vec approv
monotherapi treatment unresect melanoma replimun engin potent isol increas
tumor select express seri immune-stimulatori transgen increas potenc across pipelin lead
asset current phase i/ii studi checkpoint-respons tumor type melanoma non-
melanoma skin cancer bladder cancer microsatellit instability-high cancer alon combin
opdivo nivolumab bristol-my squibb unrat provid studi drug separ registration-direct
phase ii trial collabor regeneron unrat cutan squamou cell carcinoma cscc set begin
repres potenti fast-to-market strategi less-crowd indic studi random control
trial plu regeneron libtayo cemiplimab like t-vec express gm-csf promot recruit
dendrit cell tumor site compani asset addit express antibodi
expect enter phase i/ii trial less ici-respons tumor anticip result studi well
replimun asset express well immun activ ligand
report provid steadi stream catalyst
see number factor provid replimun strong posit ov solid tumor i/o space
manag experi develop imlyg fda-approv oncolyt viru
rel derisk platform base similar imlyg key improv potenc formul
sound scientif rational behind encod transgen potenti favor safeti profil via local express
clinic program expect includ potenti registr studi data
replimun clinic program drive steadi flow non-binari catalyst
initi registration-direct phase ii studi /- cemiplimab cscc
initi phase studi /- less ici-respons tumor
report initi result phase studi /- nivolumab
initi phase studi tumor
report result phase studi less ici-respons tumor
report result phase ii studi /- nivolumab
report result randomized-control phase ii studi cscc
report result phase ii studi less ici-respons tumor
page
replimun platform imlyg better replimun manag includ sever member team initi
develop t-vec biovex prior compani acquisit stay support
clinical/regulatori develop t-vec gone develop process fda-
approv ov provid team uniqu expertis i/o space reunit replimun understand
team initi set use specif return assess platform option replimun
lead asset replic vector like t-vec express gm-csf carri specif delet increas
tumor select reduc pathogen viru howev import featur differenti replimun
asset first particular strain use replimun platform select screen strain kill potenc
mani tumor type second addit gm-csf express gibbon ape leukemia viru surfac glycoprotein
galv-gp protein increas direct kill tumor cell immun stimul via immunogen cell death
result greater tumor control galv-gp-express viru vs dose viru without galv-gp mous
xenograft studi see figur therefor expect greater potenc vs similar dose imlyg subsequ
product replimun layer addit transgen promot antitumor immun respons tumor type less
respons ici treatment
believ extens clinic commerci experi imlyg substanti de-risk replimun asset
could certainli differ advers event profil associ differ strain presenc galv-
gp protein us parallel hsv platform combin manag experi hsv-base ov make us feel
comfort immulyt platform safeti inde yet seen safeti data replimun
on-going trial fact studi enter phase ii portion us suggest extrem safeti
signal preclud dose addit patient cohort term efficaci t-vec approv monotherapi
data combin studi t-vec ipilimumab pembrolizumab melanoma indic
addit t-vec substanti increas respons rate ici therapi vs ipilimumab vs pembro
see figur without appreci ad advers event us data provid rough efficaci benchmark
caveat patient popul differ treatment histori prior checkpoint inhibitor treatment
characterist superfici inject tumor could show differ respons subsequ therapi limit util
cross-trial comparison importantli data provid clear rational use hsv system encod ici
rais respons rate cancer
amgen imlyg poster-child success oncolog launchwhi expect replimun see better uptak
asid potenc replimun develop asset coupl addit key differ imlyg
replimun use formul allow storag month compar imlyg must
store intend use directli thaw take minut abil
store replimun product refriger could expand patient access treatment center may
facil storag imlyg label limit patient superfici lesion easily-
inject nodal tumor intratumor administr on-going checkpoint inhibitor combin trial similar
patient criteria melanoma estim compris third patient present stage iii/iv diseas
expect lower fraction non-cutan tumor replimun asset also administ compani
includ superfici nodal lesion well image-guid inject deeper/viscer tumor enabl broader
treatment melanoma well cancer type per manag major viscer inject replimun
trial perform via ultrasound guidanc understand fairli simpl familiar procedur
radiologist replimun also engag intervent radiologist broadli believ help increas
uptak note addit oncolyt virus sever cancer therapeut deliv via inject
page
develop includ buy unrat unrat other clinic
experi intratumor administr therapeut option continu grow anticip better uptak
replimun ov combin function cancer vaccin sting/rig-i agonist promot anti-cancer immun
replimun asset oncolyt virus broadli far ici combin approach develop
sever shown earli data suggest better respons rate surviv metric compar checkpoint
inhibitor monotherapi discuss see figur replic oncolyt virus engag multipl immun
pathway promot anti-tumor respons includ direct kill cancer cell enhanc tumor antigen
present recognit cell like cancer vaccin stimul innat immun system promot
cell infiltr tumor like sting/rig-i agonist therefor believ well-design ov ici program theoret
potenti yield better respons sting agonist ici vaccin ici combo similar patient particularli
tumor type low ici respons rate howev practic depend effici induct immunogen cell death
immun stimul ov thu far replimun preclin data shown induct increas cell
infiltr tumor regress tumor well establish immun memori indic adapt immun
respons moreov clinic studi t-vec stage iiic iv melanoma patient similarli shown increas
effector cell infiltr tumor anticip futur clinic data replimun includ data anticip
may includ similar analys tumor microenviron character immun cell subset therein provid
direct comparison t-vec
checkpoint combo set could bring exposur broad popul ici expand earlier treatment line
addit expans new cancer type agent increasingli move earlier line cancer treatment
provid exposur larger patient popul new cancer therapi typic initi evalu late-stag
treatment-refractori patient promis signal efficaci combin provid path expans
line treatment melanoma non-melanoma skin cancer bladder cancer associ larger patient
number gener believ mani immunotherapi combin includ ov vaccin immun modul
like work best earlier treatment line rather attempt sequenti treatment tumor develop
resist instanc data present hint increas recurrence-fre surviv advanc
melanoma patient treat neoadjuv t-vec vs surgeri alon suggest rational use
set boost efficaci cemiplimab current approv us europ patient
metastat local advanc cscc regeneron also evalu drug adjuv neoadjuv set addit
cancer type although current model penetr cscc set potenti expans
popul could provid upsid
collabor provid central replimun strategi replimun posit asset
add-on therapi believ smart approach given aforement expans
agent indic treatment line base mechan ov treatment shown increas pd-
express tumor replimun collabor regeneron cemiplimab cscc reduc spend
compani share trial cost enabl replimun rapidli move pivot studi indic
less crowd mani i/o space bm collabor provid replimun studi drug evalu
multipl cancer type without sign away commerci right either asset
robust activ deal-flow past month suggest strong interest big pharma viral immunotherapi
saw acquisit includ merck unrat acquisit viralyt mm janssen unrat
page
acquisit benevir mm up-front plu mm mileston boehring ingelheim privat
acquisit mm mm merck bi prior collabor compani
respect acquisit target merck pay premium transact addit acquisit collabor
big pharma ov compani signal pharma confid viral immunotherapi strong contend
expand immunotherapi efficaci replimun trial partner bm also licens agreement psioxu
therapeut privat evalu oncolyt adenoviru combin nivolumab regeneron clinic
suppli agreement sillajen unrat renal cancer
replimun invest manufactur right time understand manufactur replic hsv gener
less challeng non-repl gene therapi vector aav nonetheless view commercially-scal
intern manufactur strategi posit signal genet medicin space overal juli replimun sign
leas squar foot manufactur facil framingham facil capac expect
suffici support full commerci compani product candid anticip complet
meantim replimun reli manufactur clinic product compani registration-
direct studi cscc current anticip read believ replimun invest intern manufactur
well-tim respect commerci
risk replimun thesi
replimun preclin result may translat clinic set cell cultur anim model provid
mechanist proof concept therapi recapitul featur cancer instanc transplant-bas
system tumor form matter day alway develop complex microenviron seen
tumor develop patient cours year tumor genet engin anim model often
less heterogen tumor patient experi perform differ cell line may captur rang
respons expect patient divers genet background xenograft system human cell
tumor fragment engraft mice necessit use immunodefici host anim make difficult
evalu immun impact therapi differ limit predict valu preclin model
case hsv-base therapi hsv infect mous rat cell effici infect human cell could lead
underestim efficaci also unanticip advers event replimun anim data demonstr inject
agent tumor trigger regress uninject tumor term abscop effect howev
differ size immun system biolog human rodent could limit extent distant tumor
respond local inject
understand tumor-immun interact remain incomplet replimun approach rational select
transgen express product reli understand immun system interact tumor
could activ recogn elimin cancer cell much progress made understand tumor-
immun interact last decad mani unknown remain exampl predict biomark respons
differ type immunotherapi still lack addit efficaci oncolyt virus depend balanc
anti-vir anti-tumor immun immun respons viru stronger respons
tumor viru could clear quickli administr efficaci differ human mous
immun system infect limit abil predict optim featur skew respons tumor similarli
scientif rational incorpor howev fulli understand
mechan might promot resist approach preval may human t-vec data us
somewhat de-risk biolog possibl asset may provid suffici immun
page
stimul overcom immunosuppress tumor microenviron notabl thu far seen
immunocompet anim data transplant cell line lymphoma also show sensit
alon higher dose make imperfect model colder tumor addit experi dose regimen
combin immunotherapi limit combin biolog synergi may under-perform term efficaci
due sub-optim dose schedul compon
oncolyt viru platform develop combin ici creat competit patient
includ amgen t-vec clinic trial agent melanoma cancer
beyond t-vec seri viral immunotherapi agent develop similar spectrum indic
includ merck cavatak compani receiv acquisit viralyt phase studi
melanoma cavatak shown monotherapi respons rate higher t-vec cavatak ipilimumab
shown higher respons rate compar t-vec ipilimumab orr vs orr interim data cavatak
pembrolizumab combin studi melanoma reach best overal respons rate line seen t-
pembro cavatak approv could provid steeper competit replimun lead asset melanoma particular
ov could administ via intraven inject see figur abl circumv challeng neutral
antibodi associ system exposur could compet replimun asset offer conveni
ici combo strategi develop may outcompet ov core mechan oncolyt virus kill
lysi tumor cell releas tumor antigen via immunogen cell death also accomplish
chemotherapi agent anthracyclin cyclophosphamid taxan evidenc approv number
combo bulk benefit confer replimun asset induct may see
limit improv respons seen combo scenario even ov combin regimen
approv uptak could limit due establish dose regimen combo
preclin mous data suggest unlik least given increas potenc vs
tumor model see figur larg number combin addit immunotherapi agent eg
gitr agonist target therapi current develop believ local express immun stimulatori
biolog could improv respons via establish wider therapeut window elimin reduc toxic
associ system deliveri howev combin system regimen accept efficacy/tox profil
could develop may reduc usag replimun product
requir intratumor inject replimun product may limit uptak although larg number
intratumor immunotherapi agent develop discuss intratumor administr may still
view less conveni orally-deliv chemotherapi iv-deliv treatment could parallel anti-
dose regimen requir intratumor administr replimun asset could therefor limit uptak
addit replimun expand potenti pool patient deep/viscer tumor use
image-guid inject facil local commun hospit may equip perform procedur
unanticip advers event issu may preclud approv restrain penetr note believ
clinic experi t-vec provid substanti de-risk immulyt platform base similar hsv biolog
transgen subtl differ hsv strain incorpor galv-gp transgen could theoret lead
unanticip advers event cytokin releas syndrom
page
replimun may abl secur ip asset march replimun file seri patent
applic immulyt platform applic patent cooper treati pct us provision
applic per compani see page none patent yet grant earli stage examin
begun european applic nation phase thu believ replimun develop key
optim hsv oncolyt platform ip yet secur patent protect
page
figur replimun pipelin focus solid tumor progress checkpoint-respons indic immunolog cold cancer type
page
chardan cscc model model mm risk-adjust sale npv/share
figur csccwe model calendar launch us replimun fiscal year initi price lead mm risk-adjust sale
page
million sale geographi unit state sale million sale yoy statespopul cscc us cscc pt cured/treat cscc pt cured/treat treat patient sale penetrationu launch price price successu penetr inc
chardan ici-respons tumor model model mm risk-adjust sale npv/sh
figur model calendar launch replimun fiscal year initi price us excerpt lead mm risk-adjust sale
page
million sale geographi unit state sale million sale yoy statespopul melanoma patient stage iii/iv patient stage iii/iv oncolyt viru ov patient treat ov treat treat imlyg treat patient treated/year price sale statespopul bladder cancer patient present w/ locally-adv /met present w/ locally-adv /met patient w/ local recur post local recur post local total patient advanced/met patient fail elig oncolyt viru ov patient treat ov treat treat patient treated/year price sale statespopul cancer patient msi-high patient msi-high patient refractori elig oncolyt viru ov patient treat ov treat patient treated/year sale replimun group inc
catalyst replimun anticip multipl data readout next month
corpor report chardan catalyst display calendar year
figur catalystsiniti clinic data lead asset anticip data expect
page
dateeventchardan /- cemiplimab initi trial csccrandom control trial potenti support product /- initi pi/ii studi tnbc cancer typesexpress galv-gp target less ici-respons cancer indic competit pcd nci-sponsor t-vec combo studi melanomaol studi evalu t-vec pembro stage iii-iv pt drr /- nivolumab initi pi dose escal data safeti biomarkersanalysi evalu immun infiltr phenotyp vs competit pcd merck pi trial ici mel nsclc given iv pembro nsclc bladder ipi pembro competit pcd amgen/u arizona studi t-vec csccunlik replimun cscc studi combo /- data pi studi portion tnbc cancer typesw look immun activ without tx-associ system initi pi trial non-respons cancer typesexpress galv-gp target cold in-hous sq ft framingham facil come on-lineexpect manufactur product clinic competit initi pi studi transgen solid tumorsvaccinia-bas invir io platform collab bioinvent /- nivolumab safeti efficaci data portion warm tumor studyt-vec pembro orr cr mel look similar/bett /- cemiplimab safeti efficaci data studi cscccemiplimab alon orr approv look higher cr /- data trial tumor type tnbc efficaci comparison combo current clinic runway march cash fund oper calendar model rais calendar post nivo data cr complet respons cscc cutan squamou cell carcinoma dor durat respons drr durabl respons rate hnscc head neck squamou cell carcinoma ici immun checkpoint inhibitor intratumor iv intraven mel melanoma nsclc non-smal cell lung cancer ol open label orr overal respons rate os overal surviv pcd preliminari complet date progression-fre surviv pr partial respons tnbc tripl neg breast cancer replimun group inc
pipelin replimun immulyt platform target rang solid tumor /- ici
corpor report chardan mileston display calendar year
figur replimun expect move disclos product clinic multipl data readout next month
page
product candidatenear-term milestonesww rightsstag developmentpreclinphas initi pi trial replimunereplimun initi trial phase ii /- nivolumab express gm-csf galv-gpmelanoma nmsc bladder cancer msi-h /- express gm-csf galv-gpcutan squamou cell /- nivolumab express gm-csf galv-gp /- galv-gp non-respons tumor pi data /- nivolumab pcd studi initi pi trial pi data readout data readout inc
immulyt platform next-gen ov enhanc lytic immun stimul activ
unmet need oncolog minor patient respond checkpoint inhibitor even approv indic
interact immun system cancer cell
overal tumor microenviron tme shape
trajectori cancer progress respons
cell recogn tumor neoantigen
produc express mutat protein
cancer cell cell within tme
tumor associ macrophag myeloid-
deriv suppressor cell express inhibitori
ligand immunosuppress factor
limit anti-tumor activ immun cell
pathway block signal suppress
blockad enhanc interact
cell antigen-pres cell trigger
immun respons inhibit block
exhaust cell alreadi respond
clinic studi support approv shown
durabl respons last sever year
howev rate respons ici vari dramat
 melanoma patient show primari
resist develop resist
initi respons
adapt siu et al replimun chardan
figur checkpoint inhibitor transform standard care mani tumor type unmet need remain
page
respons rate approv liver inc
replimun pipelin design address cancer indic differ level ici respons
adapt replimun literatur chardan
figur replimun pipelin includ oncolyt viru asset target hot cold tumor
hot tumor gener show highest respons rate checkpoint inhibitor typic characterist
robust infiltr cell presenc antigen cell could recogn foreign
high tumor mutat burden often found tumor caus carcinogen non-smal cell lung cancer uv light melanoma high
number mutat increas frequenc antigen term neoantigen altern tumor cervic cancer close
associ virus human papillomaviru hpv express viral antigen recogn target cell
tumor typic respond well checkpoint inhibitor exampl pancreat cancer
could stem poor recognit tumor cell immun system poor infiltr cell tumor immun exclus and/or
presenc immune-suppress signal tumor microenviron aris suppress cell type tumor-associ
macrophag regulatori cell myeloid-deriv suppressor cell
tumor also typic lower mutat frequenc therefor fewer potenti neoantigen recogn
set therapi like ici releas break immun system like suffici believ addit agent
promot initi establish prime immun respons address issu suppress tme like need
page
respons checkpoint inhibitorsimmunosuppression/immun exclus inc
oncolyt virus design strengthen immun respons tumor via multipl mechan
multipl step cancer immun cycl stimul
innat adapt arm immun system
oncolyt virus act directli kill cancer cell via
replic viru insid tumor cell trigger kill
lysi cancer cell via immunogen cell death
cell death associ releas
signal die cancer cell atp calreticulin
known damage-associ molecular pattern
damp attract activ antigen present
cell apc dendrit cell tumor site
apc present antigen cell trigger
addit element viru call
multipl innat immun signal pathway tlr
sting rig-i current evalu
efficaci number clinic i/o studi
ov also increas express mhc class
complex lead better antigen present
intratumor inject oncolyt virus lead respons
uninject tumor term abscop respons due
activ system anti-tumor immun
adapt bommareddi pk et al chardan
figur oncolyt virus stimul innat adapt arm immun system
page
us potent ov would combin potenti benefit
person cancer vaccin broader immun stimul
capac sting tlr agonist off-the-shelf
talimogen laherparepvec t-vec imlyg fda-approv oncolyt viru limit
t-vec initi develop biovex acquir
product base engin strain dna viru herp
delet gene neurovirul factor reduc
pathogen viru caus preferenti viral replic
insid cancer cell defect pkr signal delet gene
enhanc immun respons antigen present
addit delet t-vec engin express
gm-csf promot anti-tumor immun via recruit
antigen-pres cell increas cell respons
t-vec approv octob treatment unresect
melanoma via inject access tumor lesion
recommend dose total inject volum start
dose plaque-form unit pfu /ml subsequ dose
note appear heavili focus
develop t-vec particularli outsid melanoma new
t-vec approv base phase studi compar t-
gm-csf inject stage iiib-iv melanoma patient
primari endpoint durabl respons rate drr defin
object respons last month result summar left
t-vec arm met drr endpoint median respons
reach arm median month follow-up
studi show signific improv overal surviv
os gm-csf
limit uptak t-vec due part emerg agent
adapt andtbacka et al chardan
figur single-ag t-vec approv melanoma
overshadow checkpoint inhibitor similar better respons rate
page
ici t-vec work better togeth melanoma expect ov/ici synergi extend cancer
though approv monotherapi t-vec sinc evalu
combin product clinic
random phase ii studi patient unresect
melanoma stage iiib iv show object respons rate
patient receiv t-vec ipilimumab versu receiv
ipilimumab alon patient respect
single-arm phase ib studi t-vec combin keytruda
pfu/ml follow week later pfu/ml
repeat everi week show orr patient
achiev complet respons vs prior keytruda studi
importantli studi show regress inject well uninject
lesion abscop effect without major safeti signal beyond ici alon
regress uninject lesion import indic system
immun respons mount tumor
system respons us critic lesion may
inject set metastat diseas
addit expect system memori respons
protect potenti outgrowth futur lesion
respons t-vec seen patient low baselin
intratumor cell level interferon gamma signatur
patient high cell number interferon gamma
like respons single-ag
complet respons patient unlik respond alon
therefor support idea ov could increas ici respons rate
possibl mechan t-vec increas intratumor cell infiltr
level make look like respons tumor
see ov proof-of-principl believ next-gen ov product
better particularli less immune-respons colder tumor
adapt riba et al chardan
figur t-vec combin show respons even melanoma
patient low intratumor cell number increas upon
page
patient lowbaselin cell inc
replimun immulyt platform incorpor fusogen protein galv-gp increas ov potenc immunogen
replimun immulyt platform also base hsv
import differ t-vec
replimun isol strain hsv volunt
get cold sore screen abil infect
t-vec gene delet
howev replimun also ad constitut
fusogen version membran glycoprotein
gibbon ape leukemia viru galv-gp r- induc
cell fusion via bind receptor
presenc galv-gp increas kill tumor
cell oncolyt hsv virus top left spread viru
within tumor top right enabl greater activ per amount
viru dose
replimun lead asset express galv-gp gm-csf
preclin mous data show oncolyt hsv carri
gm-csf t-vec togeth galv produc
stronger tumor growth suppress similar viru
effect due fact galv-gp express
increas marker immunogen cell death lower
panel potenti lead stronger immun respons
note experi employ
immunocompromis mous model lack cell
would expect even greater differ fulli
adapt replimun chardan
figur express galv-gp oncolyt viru increas cell kill viru spread
page
lung cancer xenograft treat inject pfuin vitro cell fusion assayviru w/o galvviru galv replimun group inc
replimun platform offer key advantag t-vec
adapt replimun corpor report chardan
figur amgen t-vec shown lacklust sale see sever import differ replimun platform us could translat better uptak tumor type
page
strain select potenc replimun test strain abil infect kill tumor cell vitro assay select potent strainengin delet delet insert gm-csf delet delet insert gm-csf insert galv-gp modif use t-vec enabl select replic tumor cell enhanc immun respons galv-gp promot fusion/death tumor cell immun stimulationadministrationintratumor approv inject non-viscer lesion cutan subcutan nodal intratumor cutan subcutan nodal deeper lesion inject imag guidanceth abil inject tumor found deeper bodi may make suitabl broader rang patient viscer month refriger long-term storag refriger simplifi distribut increas patient access potenti lead better uptak replimun group inc
lead candid trigger tumor regress increas cell immunocompet preclin model
promot regress inject uninject
tumor immunocompet rat transplant model
experi top panel right flank
tumor inject everi day start
day pfu tumor
show regress tumor treat
vehicl continu progress inset
note rat cell rel resist
infect hsv compar human cell
might expect superior infect human
howev less-frequ dose human
separ seri mous model experi
infiltr cell tumor mice
treat mous surrog compar vehicl
impact seen inject
notabl seen t-vec treatment
induc upregul support rational
combin therapi
adapt replimun chardan
figur induc regress inject uninject tumor immunocompet model accompani
increas infiltr cell tumor
page
also show synergi preclin model
adapt replimun chardan
figur combin immunocompet mous model increas regress frequenc inject uninject tumor
continu expans inhibitor backbon therapi across rang cancer indic demonstr improv respons
combin monotherapi fast becom core strategi immuno-oncolog space
experi immunocompet mice balb/c strain use tumor line resist treatment show regress inject
uninject tumor half anim inject high dose
importantli combin increas number regress high-dos produc regress mice treat
sub-optim dose respons otherwis infrequ suggest synergi therapi
page
clinic strategi increas efficaci checkpoint-respons solid tumor indic
trial evalu safeti efficaci monotherapi combin
adapt replimun chardan
figur replimun clinic program includ collabor clinic studi incorpor agent
bm collabor studi design evalu safeti monotherapi combin nivolumab
expect safeti data would translat combin agent
phase portion includ patient advanc metastat non-neurolog cancer progress prior treatment phase
ii portion prior exposur allow melanoma cohort remaind patient
note respons rate vari across tumor type rate complet respons low melanoma replimun aim
improv upon number includ cr rate among secondari object phase ii portion nivo trial
studi cutan squamou cell carcinoma cscc collabor regeneron design potenti registr trial
patient random receiv cemiplimab regeneron vs cemiplimab alon
expect data non-melanoma skin cancer nmsc cohort phase ii portion nivolumab studi provid earli
visibl expect random cemiplimab trial differ agent gener shown similar activ
page
clinic trial suppli collabor agreement bristol-my squibbclin trial collabor agreement regeneron share trial cost anticip data readout pi data biomark individu cohort data readout enrol complet primari data start inc
phase studi assess direct inject image-guid inject deeper tumor parallel cohort
adapt replimun trial-in-progress poster present chardan
figur trial design phase portion nivolumab studi includ intra-pati dose escal follow expans combin nivolumab phase ii dose
phase portion patient assign cohort base tumor access cohort receiv direct inject superfici nodal
tumor cohort receiv image-guid inject ultrasound ct deeper viscer tumor
expans cohort right blood sampl biopsi taken baselin day use biomark analys
believ biomark analys expect import validation/test propos mechan action may use
benchmark earli t-vec data inter-tri comparison caveat mind
page
primari object safeti profil alon combo nivolumab determin recommend phase ii dose object assess biolog activ via tumor size inflamm necrosi biodistribut shed level antibodiesbiomark analys immun cell cytokin profil isoplexi gene express profil base oncolyt viru inflammatori signatur gene panel nanostr analysi cell infiltr express tumor tissu via multiplex histolog imagingdos multipl tumor inject volbiomark analysesfor pi expans phase ii cohort intra-pati dose escal tumor dose volumepfu/ml dose inc
replimun enrol patient phase ii portion studi
adapt replimun trial-in-progress poster present chardan
figur design phase ii portion phase i/ii nivolumab combo studi
expans segment phase portion patient phase ii part studi inject via direct image-guid
inject patient divid separ inject cohort total volum ml dose biomark analys
conduct sampl taken baselin day
primari object portion trial includ
safeti toler combin nivolumab
efficaci term object respons rate orr assess recist criteria
secondari exploratori object studi includ addit metric efficaci durat respons dor cr rate diseas control rate
progression-fre surviv landmark surviv year addit aforement biomark analysi
note interpret contribut anti-tumor efficaci may challeng studi due checkpoint nativ statu
cohort obvious comparison made histor control use approv agent respect indic unless
effect dramat may difficult confid assess impact base per group
expect encourag data cohort either form higher orr greater number vs expect monotherapi
would trigger expans random studi subset indic
non-melanoma skin cancer nmsc cohort includ cutan squamou cell carcinoma among skin cancer provid first
signal kind activ expect registr cscc studi
page
replimun fast-to-market strategi /- regeneron therapi cemiplimab aim increas cr rate
cutan squamou cell carcinoma cscc form non-
melanoma skin cancer kill people/year us
sun exposur ie uv damag major risk factor
diseas often diagnos rural area
compat refriger storag
could improv access patient unabl
uv damag associ high tumor mutat
burden make cancer like recogn
foreign immun system respond i/o
earli stage diseas manag surgeri
topic therapi fluorouracil imiquimod
photodynam therapi radiat therapi
approxim cscc undergo metastasi
region lymph node distant locat
cemiplimab libtayo approv fda
patient metastat cscc local advanc cscc
candid cur surgeri radiat
system therapi approv indic
ie market crowd hot
approv base studi show
respons rate patient show cr
given increas cr rate seen upon combin
t-vec pembro melanoma expect similar
effect replimun registration-direct phase ii studi
describ earlier could see hint
adapt migden et al fda gov chardan
figur cemiplimab approv cscc base solid respons rate
page
full efficaci seen pt metastat local advanc csccthi graph pt metastat respons durabl mo inc
one number oncolyt viru therapi develop melanoma hot tumor
adapt corpor report clinicaltri gov chardan
figur sever ov-bas therapeut clinic trial typic checkpoint-respons tumor indic
page
namephasepcdindicationnviru and/or refractori solid superfici deep/viscer given everi week /- nivo everi wk inject cycl progress us suggest extrem safeti signal pi portion combo includ pt melanoma nmsc bladder msi-h cancer tx indic melanoma pt prior allow outcom includ time-frame outcom includ biolog activ vector biodistribut respons signal mdor mosamgenimlygicphas cutan sub-cut nodal lesion imlyg everi week pembro everi week vs placebo pembro trial oncolyt viru combin trial limit pt access cutan sub-cut nodal lesion deep/viscer access combo show orr w/ cr pib studi outcom us would posit read-across derisk ov approachviralyt merck cavatak type cutan sub-cut nodal lesion pembro inject day interv total outcom incid dose-limit toxic interim data show borr pt includ reduct inject uninject lesion grade advers event across pt note coxsacki viru transgen capac limit incorpor transgen move colder tumor comparison hsv cargo capac kb adenovir vector carri unresect melanoma cutan node metastasi ol cyclophosphamid pembrolizumab onco given either dose respect unlik trial studi includ chemotherapi prime day prior ov administr treatment regimen outcom treatment-emerg outcom includ orr chang immun cell subset til us patient progress agent may need potent immun stimul gm-csf chemo primingpsioxusenadenotucirevphas advanc solid tumor hnscc ucc enadenotucirev paclitaxel platinum-resist patient outcom dose-limit tox outcom max toler dose iv administr attract potenti eas deliveri therefor uptak exposur adenoviru bloodstream could result antibody-medi neutral repeat dose inc
deliv potent immun activ factor tumor
figur design promot cell function immunosuppress tumor microenviron minim system toxic
potent cell activ requir multipl signal recognit target antigen apc cell receptor tcr costimulatori signal
bind ligand antigen present cell promot cell prolifer well addit interact amplifi respons establish
mention therapi reduc exhaust exist cell respons approach act stimul cell prime
secondari lymphoid organ combin strategi togeth produc stronger respons also greater immun relat toxic eg
patient melanoma studi requir hospit admiss due immune-rel advers event discontinu rate seen
system deliveri immun approach eg high-dos recent stimul also produc immun relat advers event
highlight potenti local deliveri express improv safeti profil i/o agent
us key question consist express immun activ inject tumor abl trigger abscop respons
uninject lesion patient believ replimun select transgen act antigen present prime step cancer
immun cycl drain lymph node increas likelihood comparison believ local inject express agent would
less like produc strong abscop respons due activ tumor microenviron
page
insert gm-csf insert galv gm-csf recruit apc increas cell respons galv increas cell kill viral spread aim increas depth frequenc checkpoint inhibitor antibody-lik protein blockad enhanc cell activ apc may act elimin regulatori cell high efficaci rate melanoma combo hinder autoimmun toxic local express tme could circumv tox keep activ agonist ab stimul innat adapt immun multipl mechan activ dendrit cell induc inflammatori cytokin secret cell activ memori anoth costimulatori pathway promot cell prolifer memori cytotox metabol memori format local express also aim avoid tox system activ inc
mous surrog show efficaci lower dose vs cooper induc immun memori
adapt replimun chardan
figur ad backbon produc viru abl clear inject uninject tumor lower dose establish immun memori
replimun preclin experi show incorpor viru enabl tumor clearanc dose clear tumor
particularli uninject one set alon
sinc cell line use sensit higher dose draw conclus expans tumor type
resist re-challeng clearanc combo set demonstr establish immun memori tumor
page
mous surrogatetop immuno-compet mous model lymphoma treat low viral dose pfu bottom viru tumor re-challeng day right side tumor inject virusgrowth control re-challeng micemous surrogatemous surrog daysstudi daysstudi daysuninjectedinject replimun group inc
preclin data show addit individu immun stimulatori ligand also increas potenc
adapt replimun chardan
figur addit backbon individu without increas tumor clear inject uninject
poster replimun present data show addit individu mous gene also enhanc potenc mous
effect seen inject right uninject left tumor indic system immun respons sub-
effect uninject tumor figur particularli notabl given expect
express cell inject tumor
note data repres incorpor individu immun stimulatori ligand asset includ well
therefor could expect stronger anti-tumor immun activ viru carri compon
clinic evid support benefit combin agonist phase studi show orr
metastat melanoma without prior immunotherapi upon treatment combin antibodi tremelimumab agonist
mab earlier studi tremelimumab alon reach orr unresect melanoma though caveat regard
draw conclus cross-trial comparison appli howev much interest potenti activ tumor
also evid combin element agent number anim studi shown agonist sensit tumor
alter myeloid cell tumor cell prime combo anoth agonist chemo show earli sign
tumor reduct phase ib studi pancreat cancer howev patient experienc ae lead discontinu therapi
treatment-rel ae underscor potenti local activ widen therapeut window
agonist also cooper promot anti-tumor respons poorli immunogen tumor
degre tumor respons could certainli improv potent combin better therapeut window via local express
page
among suit next-gen oncolyt virus develop cold tumor
adapt corpor report clinicaltri gov chardan
figur sever next-gen ov incorpor vector antibodi multipl immun modul clinic
page
namephaseindicationnviru trial start less respons eg gm-csf nivolumab see local express ab system promis strategi avoid toxic associ combin given system us data demonstr immun respons uninject tumor import support mechan impli preclin start anticip solid cancersn/avaccinia develop collabor bioinvent believ combin would provid clearer path market indic agent approv compar start less respons plan evalu tumor type low ici respons rate efficaci bar may low demonstr favor safeti import given tox issu report system agonist advanc epitheli antibodyit/ivmonotherapi cohort singl dose iv cohort singl dose day primari outcom incid advers event success iv deliveri would major advantag though neutral antibodi remain concern repeat submiss anticip tumor /- checkpoint inhibitor fulli replication-compet hsv vector altern safeti element mous data murin surrog show tumor clearanc immun cell infiltr resist re-challeng dose escal basket studi plan determin safeti toler dose replimun group inc
figur replimuneincom statement million except ep
page
million except gener oper incom incom incom incom incom incom loss common basic dilut incom per share ep incom per share ep size incom gener oper incom incom incom incom incom incom loss common inc
sale key product
figur replimuneproduct revenu million
page
therapeut advanc solid solid pipelin yoy product yoy replimun group inc
figur replimunediscount cash flow dcf analysi million
page
million except per share net depreci capit increas work defer non-cash free cash first year cash unlev free cash period discount period discount year mid-year factor free cash valu unlev free cash pv forecast unlev free cash valu perpetu growth valu termin termin ebitda xenterpris valu per dilut assumptionswacc calculationsbal sheetdcf valu alloc product cash fiscal year end fiscal year end project discount project discount per cash per dilut share price valu per perpetu growth market cap june share exercis stock share exercis possibl dilut million replimun group inc
